Iovance Failed to Disclose Paid Shills Promoting its Stock, Class Claims

Investors claim they were misled when Iovance Biotherapeutics covertly paid a promoter to write articles and send emails pushing its stock until the Securities Exchange Commission stepped in with a cease-and-desist order.

Read more